Title:
新規化合物及びその適用
Document Type and Number:
Japanese Patent JP7383308
Kind Code:
B2
Abstract:
The present invention relates to a novel compound and application thereof in the inhibition of HBV gene expression. The structure of the compound comprises an interfering nucleic acid for inhibiting HBV gene expression, transition points, and delivery chains of the interfering nucleic acid. By means of the delivery chains, two or three N-acetylgalactosamines can be introduced to an antisense strand 3' end of such siRNA, and two or one N-acetylgalactosamine can be correspondingly introduced to a sense strand 5' end, the total number of the introduced N-acetylgalactosamines being four. In vitro and in vivo pharmacological experiments prove that such a novel compound can continuously and efficiently inhibit HBV gene expression.
Inventors:
Lu Xue Ching
Mu Chuo
Wang Shenjun
Do Yangchun
Mu Chuo
Wang Shenjun
Do Yangchun
Application Number:
JP2021577836A
Publication Date:
November 20, 2023
Filing Date:
June 23, 2020
Export Citation:
Assignee:
Kilonova (Siamen) Biopharma Company Limited
International Classes:
C12N15/113; A61K31/7105; A61K31/713; A61P1/16; A61P31/20
Domestic Patent References:
| JP2017538679A | ||||
| JP2014527401A | ||||
| JP2018520685A |
Foreign References:
| CN109331185A |
Attorney, Agent or Firm:
Sachiko Takeda